about
Production of lentiviral vectorsTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyCongenital defects in neutrophil dynamicsGene therapy on the moveProtein Kinase C δ: a Gatekeeper of Immune HomeostasisTherapeutic potential of optogenetic neuromodulationLentiviral vector transduction of spermatozoa as a tool for the study of early development.Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.The future potential for cocaine vaccines.Molecular mechanisms of retroviral integration site selection.Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.Improving the safety of cell therapy products by suicide gene transferDamaging the Integrated HIV Proviral DNA with TALENs.Bacterial delivery of TALEN proteins for human genome editingClinical applications of gene therapy for primary immunodeficiencies.Prevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow CellsTransplantation of Photoreceptor Precursors Isolated via a Cell Surface Biomarker Panel From Embryonic Stem Cell-Derived Self-Forming Retina.Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.A genome editing primer for the hematologistFunctional Restoration of gp91phox-Oxidase Activity by BAC Transgenesis and Gene Targeting in X-linked Chronic Granulomatous Disease iPSCs.A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance.Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I.Hematopoietic stem cells for cancer immunotherapyPlatelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Lentiviral vectors for the treatment of primary immunodeficiencies.ICON: the early diagnosis of congenital immunodeficiencies.Clinical potential of gene therapy: towards meeting the demand.Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies.Integration site and clonal expansion in human chronic retroviral infection and gene therapy.Optical stimulation for restoration of motor function after spinal cord injury.Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs.An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking.Pseudotyped murine leukemia virus for schistosome transgenesis: approaches, methods and perspectives.Engineering Next-Generation BET-Independent MLV Vectors for Safer Gene Therapy.CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors.Construction of stable packaging cell lines for clinical lentiviral vector production.Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter.
P2860
Q26750586-4DCF32A8-F2B4-4E40-AFA2-051884C51B7EQ26771159-DE213611-6CC5-45B0-A4F6-85811D91BABBQ26996029-F4A94674-9EEA-43F9-B124-8F80ED45DBC6Q27007012-E73C244C-836C-4A1A-92E1-98258AE4C421Q27686992-46937851-BC89-4E24-936D-8E85A7738736Q28084334-51086109-CF4B-403F-9DCE-BA6E2DADCC6BQ33724015-97EB079C-6FF9-4FAE-A5C7-B318003C1E1CQ33782832-C618D3FD-37F0-47C0-AD65-5E7BA8A1ADADQ33881920-80445797-89DA-4F6D-8F15-CC86302A94BAQ34132804-D7376F40-45EE-4893-82CA-F9AAFE8EC2B7Q34249653-B11C0C28-3A91-4946-AD3A-BB0922233A59Q34268121-87E471C2-B57B-47F9-A4B2-EDB24230D023Q34453846-2F3F1E63-05E3-466B-A740-46277597115AQ34475249-5179F9CB-505D-427D-956B-D46AC06A9A02Q35117894-91EB3104-AAD3-4916-A748-56ED241A8D62Q35539617-2C383BE1-414C-440B-805B-E86A19887909Q35807632-506ACDB6-1105-48FD-BF69-061C17178B67Q36886550-26104D0E-CF66-4B8E-B516-ABDF9BEC4FDCQ36920437-853E67D3-B322-4A40-8773-0AD40FE67588Q36942027-57AB8DF1-2F67-42C7-9977-49AC68008BB6Q36951255-8F383A9B-3F9C-4332-97E1-0AD4405C8F5AQ37183068-24A813FC-3CF7-4A23-B489-4DAE45703A28Q37280501-84F4CB2A-435B-4240-B4DF-FB6587E92460Q37512048-4A2F5AD1-45B1-4A3F-9EC8-F00869D82C34Q37599950-1950120F-C6B5-4C86-9B06-9D41659C35F7Q37664729-6CBDFC81-5675-447C-BDF6-E09A9DDFEEC7Q38195200-C42CF85F-0129-4E65-A3F4-EC9C699673E2Q38195246-F0AA4F18-DCCE-47DE-953C-3C3353E4AFADQ38195338-9EA1CB82-FA4C-465C-BDD6-71553B1924B1Q38216460-643C8DF1-DC4B-4602-B59B-A4C06093A0F6Q38264568-9B59E252-7037-4912-ABD4-BF4EAE5A43A3Q38346731-28FCA415-2D2C-4470-8FA7-783C4963BA6EQ38899905-D1B3C98C-9AF1-417E-A17F-97D31DA8F16AQ39031463-D58ADEAA-FD2A-409E-83B6-62ECB033BB55Q39211453-BD334C65-D0B9-460B-8A47-59AABCA01264Q40156250-87302069-0A46-4C19-9D10-ED339CA43C0CQ40486239-80232DEC-A958-4D55-88B8-0354A9FDD70DQ41124092-6790B22D-B3F7-48BA-A4C5-E74F43947EE1Q41437137-01250F09-847B-47C8-A4C3-22BBADCF6A15Q41533331-2D3F2447-DC46-4A55-9DE5-089AFA49A190
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Gene therapy for PIDs: progress, pitfalls and prospects
@ast
Gene therapy for PIDs: progress, pitfalls and prospects
@en
type
label
Gene therapy for PIDs: progress, pitfalls and prospects
@ast
Gene therapy for PIDs: progress, pitfalls and prospects
@en
prefLabel
Gene therapy for PIDs: progress, pitfalls and prospects
@ast
Gene therapy for PIDs: progress, pitfalls and prospects
@en
P2860
P921
P1433
P1476
Gene therapy for PIDs: progress, pitfalls and prospects
@en
P2093
Sayandip Mukherjee
P2860
P304
P356
10.1016/J.GENE.2013.03.098
P407
P5008
P577
2013-04-06T00:00:00Z
2013-08-10T00:00:00Z